ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, March 06, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting rights
02/28/2025100,093,87388,849,752



For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer,        

Attachment



EN
06/03/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights07/31/2025100,325,22989,428,630 About Cellectis     Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology,...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/07/2025100 325 22989 428 630 À propos de Cellectis             Cellectis est une société de biotechnologie au stade clinique, qui utilise sa technologie pionnière d’édition de génome TALEN® pour développer d...

August 7, 2025 1 EN
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
FRA FRAPORT AG
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
08/05/25 August 5, 2025 1 EN
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
FRA FRAPORT AG
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
08/05/25 August 5, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
08/05/25 August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch